Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Non-Current Assets (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Non-Current Assets for 16 consecutive years, with $28.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 1.89% to $28.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $109.3 million, a 0.07% change, with the full-year FY2024 number at $26.7 million, down 3.68% from a year prior.
  • Non-Current Assets was $28.0 million for Q3 2025 at Xtant Medical Holdings, roughly flat from $27.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $28.0 million in Q3 2025 to a low of $10.2 million in Q3 2021.
  • A 5-year average of $20.1 million and a median of $26.6 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 156.76% in 2023, then dropped 3.68% in 2024.
  • Xtant Medical Holdings' Non-Current Assets stood at $10.4 million in 2021, then increased by 5.3% to $10.9 million in 2022, then surged by 154.27% to $27.7 million in 2023, then dropped by 3.68% to $26.7 million in 2024, then grew by 4.75% to $28.0 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Non-Current Assets are $28.0 million (Q3 2025), $27.9 million (Q2 2025), and $26.7 million (Q1 2025).